Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Equity Average (2016 - 2025)

Sunshine Biopharma's Equity Average history spans 12 years, with the latest figure at $23.6 million for Q4 2025.

  • For Q4 2025, Equity Average fell 2.68% year-over-year to $23.6 million; the TTM value through Dec 2025 reached $23.6 million, down 2.68%, while the annual FY2025 figure was $23.3 million, 4.1% up from the prior year.
  • Equity Average reached $23.6 million in Q4 2025 per SBFM's latest filing, down from $24.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $41.1 million in Q3 2022 to a low of -$1.0 million in Q3 2021.
  • Average Equity Average over 5 years is $19.0 million, with a median of $23.1 million recorded in 2024.
  • Peak YoY movement for Equity Average: tumbled 80.78% in 2021, then skyrocketed 6544.31% in 2022.
  • A 5-year view of Equity Average shows it stood at -$481135.0 in 2021, then surged by 6544.31% to $31.0 million in 2022, then plummeted by 30.38% to $21.6 million in 2023, then rose by 12.44% to $24.3 million in 2024, then dropped by 2.68% to $23.6 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Equity Average are $23.6 million (Q4 2025), $24.9 million (Q3 2025), and $24.2 million (Q2 2025).